In most cancer types, the expression levels of lenvatinib target genes generally showed a negative correlation with the level of CD8+ T cell infiltration, suggesting that lenvatinib treatment may increase the degree of infiltration of CD8+ T cells. The gene discussed is CD8A; the disease is cancer.